Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael Kahn
University of Southern California, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
PRISM Pharma Co., Ltd.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Kahn has an equity interest in and receives payments for services from PRISM. He is a PI on a grant that will test PRI-724 both preclinically and in a randomized Phase II clinical trial. PRI-724 is a novel therapeutic agent owned by PRISM. Dr. Kahn's role is limited to the preclinical portion of the research. The value of the equity interest is based on a previous estimate.
Efficacy of Novel Wnt Modulator in Colon Cancer
The Wnt signaling pathway is critical for the development and progression of the majority of colon cancers. Targeting this pathway should provide a novel strategy for the treatment of patients with metastatic colon cancer. This proposal incorporates a bench to bedside Phase II clinical trial using novel small molecule agents in combination with FOLFOX/bevcaziumab, which the Principal Investigator's lab developed.
Filed on July 29, 2014.
Tell us what you know about Michael Kahn's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Michael Kahn filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michael Kahn | University of Southern California | Conflict of Interest | PRISM Pharma Co., Ltd. | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.